Antiangiogenese-Ansätze in der TumortherapieAnti-angiogenic approaches in tumor therapy

被引：0
作者：
Christine Brostjan
S. Roka
A. Gornikiewicz
J. Friedl
机构：
[1] Universitätsklinik für Chirurgie,Chirurgische Forschungslaboratorien
[2] Wien,undefined
来源：
Acta Chirurgica Austriaca | 2000年 / 32卷 / 6期
关键词：
Tumor; Therapie; Endothelzellen; klinische Studien; Tumor; angiogenesis; therapy; endothelial cells; clinical trials;
D O I：
10.1007/BF02949148
中图分类号：
学科分类号：
摘要：
Grundlagen: Tumorwachstum und Metastasierung erfordern eine ausreichende Versorgung durch Blutgefäße, die weitgehend neu gebildet werden müssen. Der Prozeß der Angiogenese bietet daher einen vielversprechenden Angriffspunkt in der Tumortherapie.
引用
收藏
页码：251 / 254
页数：3
相关论文
共 124 条
  • [1] Bhargava P(1999)A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer Clin Cancer Res 5 1989-1995
  • [2] Marshall JL(1997)Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature 390 404-407
  • [3] Rizvi N(2000)Clinical strategy for the development of angiogenesis inhibitors Oncologist 5 51-54
  • [4] Dahut W(1996)Tumor angiogenesis: a physiological process or genetically determined? Cancer Metastasis Rev 15 205-212
  • [5] Yoe J(1998)Fumagillin analog in the treatment of Kaposi’s sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team J Clin Oncol 16 1444-1449
  • [6] Figuera M(2000)Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer Br J Cancer 82 812-817
  • [7] Phipps K(1971)Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182-1186
  • [8] Ong VS(1997)Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy Invest New Drugs 15 15-28
  • [9] Kato A(1999)Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 284 1994-1998
  • [10] Hawkins MJ(2000)Tumor angiogenesis: past, present and the near future Carcinogenesis 21 505-515
12345678910